A Randomized, Double-blind, Placebo-controlled, Multicenter, Adaptive Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in the Treatment of Ulcerative Pyoderma Gangrenosum

InflaRx GmbH50 sites in 10 countries54 target enrollmentNovember 1, 2023

ConditionsPyoderma Gangrenosum

Interventionsvilobelimab Placebo

Overview

Phase: Phase 3
Intervention: vilobelimab
Conditions: Pyoderma Gangrenosum
Sponsor: InflaRx GmbH
Enrollment: 54
Locations: 50
Primary Endpoint: Efficacy of treatment with vilobelimab compared to placebo
Status: Terminated
Last Updated: 5 months ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

A randomized, double-blind, placebo-controlled, multicenter, adaptive phase III trial to investigate efficacy and safety of vilobelimab in the treatment of ulcerative pyoderma gangrenosum

Registry

clinicaltrials.gov

Start Date

November 1, 2023

End Date

July 11, 2025

Last Updated

5 months ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

InflaRx GmbH

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•18 years or older at the time of signing the informed consent.
•Investigator confirmed clinical diagnosis of ulcerative PG. Diagnosis shall be supported by clinical assessment of PG symptoms via PARACELSUS score (Jockenhofer, Wollina et al. 2019) of 10 points or more (see Appendix - Section 12.1). Note: in case of PARACELSUS score \< 10, additional justification shall be provided by the investigator to support clinical diagnosis of ulcerative PG.
•Minimum of 1 evaluable PG ulcer (other than peristomal) which qualifies as the target ulcer by meeting the following criteria (Orfaly, Reese et al. 2022): area of ≥ 5 cm 2 at screening and baseline
•circulated by intact skin
•evaluable by at least 2-dimensional measurement

Exclusion Criteria

•Patients with target ulcers exceeding 80 cm 2 .
•Patients with target ulcer in transplanted skin.
•Surgical wound debridement or negative pressure wound therapy (NPWT) for the target ulcer within 4 weeks before baseline (i.e., start of treatment with IMP).
•Patient with previous exposure to vilobelimab (IFX-1) prior to baseline (i.e., start of treatment with IMP).
•Patient receives/has received a vaccine within 2 weeks prior to baseline (i.e., start of treatment with IMP).
•Any active infection requiring systemic antibiotic or other systemic treatment or suppressive anti-infective therapy within 2 weeks prior to baseline (i.e., start of treatment with IMP).
•Patients received any systemic medical treatment for PG within 4 weeks prior to baseline
•Patients received any biological or immunomodulatory therapy for PG within 4 weeks prior to baseline (i.e., start of treatment with IMP), except existing biologic or immunomodulatory therapy used for an underlying disease (other than PG at a stable therapy with no dose adjustments for at least two maintenance doses prior to screening this is allowed to be continued.
•Patients receiving corticosteroids treatment for PG of more than 10 mg/day of prednisone or equivalent within 4 weeks prior to baseline (i.e., start of treatment with IMP).